Study guide
14.1 CPMRS Query and Reporting
Connecticut Multistate Pharmacy Jurisprudence Examination CT MPJE
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the Connecticut MPJE 1.2 Application, Fees, ATT, and Pearson VUE 1.3 Blueprint, Scoring, Retakes, and Study Strategy
2 Connecticut Regulatory Structure
2.1 DCP and the Commission of Pharmacy 2.2 Chapter 400j, 420b/420c, and RCSA 20-576 2.3 Federal vs Connecticut Law (More Restrictive Rule)
3 Pharmacist Licensure, Interns, PIC, and CE
3.1 Pharmacist Qualifications and Exam Path 3.2 Interns, Score Transfer, and Reciprocity 3.3 Pharmacist-in-Charge / Pharmacist Manager 3.4 License Renewal and Continuing Education
4 Technicians and Non-Pharmacist Personnel
4.1 Technician Registration and Certification 4.2 Community Technician Ratios (20-576-36) 4.3 Institutional Ratios and Advanced Pharmacy Technicians 4.4 Technician Limitations, Interns, and Unlicensed Staff
5 Discipline, Impairment, and Unlicensed Practice
5.1 Disciplinary Grounds (CGS § 20-579) 5.2 Impaired Practitioner Reporting and Programs 5.3 Unlicensed Practice, Penalties, and Appeals
6 Federal Drug Law Foundations
6.1 FDCA, Adulteration, and Misbranding 6.2 FDA Approval, Recalls, and OTC vs Rx 6.3 DSCSA, HIPAA, OBRA ’90, and PPPA
7 Federal Controlled Substances
7.1 CSA Schedules and Definitions 7.2 DEA Registration and Forms 222, 106, 41 7.3 Federal Controlled-Substance Prescription Rules 7.4 Inventory, Theft, Loss, and Disposal
8 Prescription Issuance in Connecticut
8.1 Who May Prescribe in Connecticut 8.2 Noncontrolled Prescription Form and Content 8.3 Controlled Prescriptions and the EPCS Mandate
9 Refills, Partial Fills, and Opioid Limits
9.1 Refill Authority (Noncontrolled and CIII–V) 9.2 Partial Fills of Schedule II Prescriptions 9.3 Connecticut Opioid Supply Limits (7-day / 5-day)
10 Administration, CDTM, and Standing Orders
10.1 Pharmacist Immunization Authority 10.2 Collaborative Drug Therapy Management 10.3 Naloxone and Opioid Antagonist Access 10.4 Emergency and Hormonal Contraception
11 Counseling, Confidentiality, and Returns
11.1 Counseling and Offer to Counsel 11.2 HIPAA and Connecticut Confidentiality 11.3 Return, Reuse, and Take-Back
12 Corresponding Responsibility and DUR
12.1 Corresponding Responsibility and Legitimate Medical Purpose 12.2 Prospective Drug Utilization Review 12.3 Exceptions and Conditions Prohibiting Dispensing
13 Transfers, Labeling, Packaging, and Delivery
13.1 Transferring Prescriptions 13.2 Labeling of Dispensed Drugs 13.3 Packaging and the Poison Prevention Packaging Act 13.4 Delivery of Drugs
14 CPMRS, Substitution, and Nonprescription Drugs
14.1 CPMRS Query and Reporting 14.2 Generic and Biosimilar Substitution 14.3 CMEA and Behind-the-Counter Products 14.4 OTC Labeling, Hazardous, and Restricted Nonprescription Drugs
15 Ordering, Records, and Inventories
15.1 Ordering and Acquisition (DEA 222/CSOS) 15.2 Distribution and DSCSA Records 15.3 Recordkeeping Content and Three-Year Retention 15.4 Controlled-Substance Inventories and CT Perpetual CII
16 Storage, Security, and Hazardous Drugs
16.1 Controlled-Substance Storage and Security 16.2 Hazardous Drugs (USP <800>, NIOSH) 16.3 Non-Pharmacist Access to Drugs
17 Compounding and Central Fill
17.1 Nonsterile Compounding (USP <795>, RCSA 20-576-69) 17.2 Sterile Compounding (USP <797>, RCSA 20-576-64) 17.3 Central Fill, 503A, and 503B Outsourcing
18 Pharmacy Permits and Practice Settings
18.1 Pharmacy License, Hours, Manager, and Signage 18.2 Nonresident, Hospital, Nuclear, and Automated Dispensing 18.3 Inspection, Closure, and Facility Discipline
14.1 CPMRS Query and Reporting
Key Takeaways Explain This Topic AI
CPMRS is Connecticut’s PDMP, run by DCP Drug Control under CGS § 21a-254(j). Pharmacies report Schedule II–V dispensations immediately upon, but in no event later than the next business day; DCP also states 24 hours or the next business day, whichever comes later.
Effective January 1, 2021, pharmacies also report gabapentin, naloxone, insulin, glucagon, and listed diabetes devices. Gabapentin is not scheduled; DCP has stated mandatory CPMRS look-up does not apply solely because it is reported. Naloxone uploads are masked from ordinary user reports.
Prescribers (or authorized agents) must query CPMRS before prescribing any CII–V intended to last more than 72 hours; ongoing CII–IV (other than CV nonnarcotic) at least every 90 days; ongoing CV nonnarcotic at least annually. If CPMRS is down, query within 24 hours of regained access.
A pharmacist, and a pharmacist’s authorized technician, MAY query CPMRS for therapy management related to the pharmacist’s practice. No person or employer shall prohibit, discourage, or impede that request (CGS § 21a-254(j)(8)).
DCP’s operational trigger for many reportable products is a supply greater than 48 hours; naloxone is reportable at any supply. Direct administration, 48-hour facility supplies, samples, and DEA-registered OTP records under 21 CFR 1304.24 are non-reportable.
Last updated: August 2026
Why CPMRS is its own Competency 3.3.1 leaf
Quick Answer: CPMRS is Connecticut’s prescription drug monitoring program (PDMP) , housed in DCP Drug Control under CGS § 21a-254(j) . Pharmacies report Schedule II–V dispensations immediately upon, but in no event later than the next business day (DCP also: 24 hours or the next business day , whichever comes later). Gabapentin and naloxone reporting began January 1, 2021 — gabapentin is not scheduled and has no mandatory prescriber look-up . Prescribers query before a CII–V intended to last more than 72 hours , then every 90 days for ongoing CII–IV and annually for ongoing CV. Pharmacists (and authorized technicians) may query for therapy management; no person or employer shall prohibit, discourage, or impede that request.
NABP Competency 3.3.1 is not “the database exists.” It is who must look , who may look , what must be uploaded , and how fast . Chapter 7 already taught that reported ≠ scheduled . This section is the operational clock.
RCSA § 21a-254-4 still recites a twice-monthly paper-era calendar (20th and 5th). That regulation has not caught the July 1, 2016 daily-reporting statute. On the MPJE, current CGS § 21a-254(j) and DCP’s PMP pages control .
Two clocks — reporting versus query
Do not collapse upload and look-up. One is a dispenser duty into PMP Clearinghouse ( pmpclearinghouse.net ). The other is a user duty in PMP AWARxE ( connecticut.pmpaware.net ).
Actor Duty Clock Source
Pharmacy / nonresident / hospital outpatient pharmacy / dispensing practitioner Report CII–V and DCP-designated products Immediately , and no later than the next business day (DCP: 24 hours or next business day , whichever is later) CGS § 21a-254(j); DCP Pharmacist Information; DCP waiver page
Prescribing practitioner or authorized agent Query before any CII–V intended >72 hours Before the prescription is issued CGS § 21a-254(j)(9); PA 15-198; DCP 2015 highlight
Prescriber, ongoing CII–IV (other than CV nonnarcotic) Re-query for continuous or prolonged treatment Not less than once every 90 days § 21a-254(j)(9); DCP 2015
Prescriber, ongoing CV nonnarcotic Re-query Not less than annually § 21a-254(j)(9); PA 16-43; DCP 2016
Pharmacist / authorized technician May query for therapy management in the pharmacist’s scope No mandatory fill-time look-up in the statute for the pharmacist § 21a-254(j); PA 19-191 (tech access Oct 1, 2019)
If CPMRS is not operational , the prescriber may still issue a >72-hour CII–V supply during the outage , but must query not more than 24 hours after regain access . That 24-hour catch-up is a prescriber sentence. It does not excuse a pharmacy from uploading yesterday’s fills when Clearinghouse is back.
What pharmacies must upload — and the 48-hour wall
DCP’s dispenser page is a checklist, not a slogan. A Connecticut-licensed pharmacy, nonresident pharmacy , hospital outpatient pharmacy, or other dispenser reports when any of the following is true:
- Schedule II–V controlled substances with a supply greater than 48 hours
- Gabapentin with a supply greater than 48 hours
- Naloxone at any prescription supply
Insulin, glucagon, diabetes devices, and diabetic ketoacidosis devices at any supply (veterinarian products for those four diabetes categories are not reportable)
Non-reportable activities DCP lists:
- A reportable drug administered directly to a patient by a prescriber
- A licensed health-care facility dispense limited to a quantity adequate to treat at most 48 hours
- A drug sample dispensed
- Inpatient hospital or nursing-home dispensing ( assisted living is not in that exemption)
- Inpatient hospice (home hospice and hospice-in-assisted-living are not exempt)
- A DEA-registered narcotic treatment program keeping records under 21 CFR 1304.24
A Saturday 30-day oxycodone fill is reportable immediately , and no later than the next business day . A 24-hour hospital discharge pack of hydromorphone can sit in the 48-hour facility exemption. Zero reports are required for days with no reportable dispensation; DCP’s waiver page says reporting is mandatory every day — open or closed , with the next-business-day catch-up when the store is actually shut. Dispensing veterinarians are the published exception: at least every seven days when they dispense more than a 48-hour CS or gabapentin supply.
January 1, 2021 added gabapentin, naloxone, and the diabetes cluster under the Commissioner’s § 21a-254(j)(2) authority to designate additional products. DCP’s notice is the exam’s favorite sentence: adding gabapentin does not change it to a controlled substance , it is not a scheduled medication , and mandatory look-up prior to prescribing does not apply . Pharmacists still upload the fill. They do not order it on a DEA 222, count it in perpetual CII, or treat a missed gabapentin query as a § 21a-254(j)(9) violation. Naloxone uploads are masked from ordinary CPMRS users ; only DCP administrators see them, for aggregate policy. Do not refuse a naloxone standing-order fill because “it will show up on the patient’s report.”
Who may look — and who may not stop them
Prescriber registration with CPMRS is mandatory for anyone who holds a Connecticut controlled-substance registration (PA 13-172). The mandatory usage clock in § 21a-254(j)(9) is the prescriber’s (or authorized agent’s).
The pharmacist clock is different. A pharmacist dispensing for a patient, or that pharmacist’s authorized pharmacy technician , may obtain CPMRS information for purposes related to the pharmacist’s scope of practice and management of the patient’s drug therapy , including monitoring controlled substances the patient has obtained. PA 19-191 (effective October 1, 2019 ) let the designated technician register for a user account. The technician accesses the program to facilitate the pharmacist’s review . The pharmacist remains responsible, including 45 CFR 164.308 administrative safeguards, and may be disciplined for the technician’s acts.
CGS § 21a-254(j)(8) is a one-sentence employment statute: no person or employer shall prohibit, discourage, or impede a prescribing practitioner, pharmacist, or pharmacist’s authorized technician from requesting the information. A chain metric that punishes “too many PDMP looks,” a PIC who tells staff “we don’t have time for CPMRS,” or a corporate block on technician registration is the violation. Corresponding responsibility (Chapter 12) still expects the pharmacist to use the tool when red flags appear; the statute does not convert every fill into a mandatory pharmacist query the way it converts a >72-hour CII into a mandatory prescriber query.
Clinical alerts DCP publishes for users — 5 prescribers AND 5 pharmacies in 3 months , daily MME threshold, concurrent opioid plus benzodiazepine — are decision-support , not automatic refuse-to-fill rules. Interstate data include Rhode Island, Massachusetts, and New York . The State does not warrant reports as complete; call the listed pharmacy if the row looks wrong, and correct Clearinghouse errors rather than arguing with the patient about a keystroke.
Realistic Connecticut scenario
A Stamford internist writes a 10-day hydrocodone for a new outpatient. That is >72 hours , so the internist or agent must query CPMRS first . The same internist’s ongoing oxycodone for cancer pain needs a look at least every 90 days . The internist’s pregabalin (CV) for the same patient needs a look at least annually . Writing gabapentin 300 mg three times daily does not trigger the mandatory look-up, even though the New Haven pharmacy will upload that gabapentin fill by the next business day if the supply is >48 hours .
The New Haven pharmacist is not required by § 21a-254(j)(9) to query before releasing the hydrocodone, but may query, and an authorized technician may pull the report for the pharmacist . If the district manager says “CPMRS looks kill our times — stop,” § 21a-254(j)(8) is already broken. If Clearinghouse is down Saturday night, the pharmacy still owes the upload no later than the next business day after it can transmit — not the old 20th-of-the-month regulation.
Official anchors
CGS § 21a-254 — electronic PDMP, 72-hour / 90-day / annual query, employer non-interference, reporting.
DCP Prescriber Information — PA 15-198 and PA 16-43 query clocks; outage 24-hour catch-up.
DCP Pharmacist / dispenser reporting — next-business-day upload; 48-hour trigger; naloxone any supply.
DCP gabapentin / naloxone notice — reported, not scheduled; naloxone masked.
DCP prescribing-practice highlights — 2015–2016 query cadence in DCP’s own timeline.